News & Updates

Secukinumab on par with adalimumab biosimilar in r-axSpA

19 Jun 2023 by

Treatment with secukinumab (SEC) shows no significant difference with adalimumab biosimilar (SDZ-ADL) in spinal radiographic progression, which remains low over 2 years, among patients with radiographic axial spondyloarthritis (r-axSpA), according to a phase IIIb study presented at EULAR 2023.

Secukinumab on par with adalimumab biosimilar in r-axSpA

19 Jun 2023

Cutaneous eruptions from ibrutinib overlap with EGFR-induced adverse events

19 Jun 2023

Several cutaneous toxicities arising from ibrutinib therapy are similar to those caused by the use of selective epidermal growth factor receptor (EGFR) inhibitors, except for petechiae, according to a study.

Cutaneous eruptions from ibrutinib overlap with EGFR-induced adverse events

19 Jun 2023

Updated CodeBreak 200 analyses boost sotorasib role in KRASG12C-mutant NSCLC

19 Jun 2023 by

In the PRO analyses of the phase III CodeBreak 200 trial, the first-in-class KRAS^G12C inhibitor sotorasib improved quality of life (QoL) of patients with pretreated KRAS^G12C-mutated advanced non-small-cell lung cancer (NSCLC) compared with docetaxel.

Updated CodeBreak 200 analyses boost sotorasib role in KRASG12C-mutant NSCLC

19 Jun 2023

What are the barriers to communication between pharmacists during transitions of care?

18 Jun 2023

Several barriers to communication exist between pharmacists during transitions of care (TOC) across healthcare settings, reports a US study.

What are the barriers to communication between pharmacists during transitions of care?

18 Jun 2023

Colon cancer survival with neoadjuvant chemo vs upfront surgery a toss-up

18 Jun 2023

In the treatment of patients with colon cancer, neoadjuvant chemotherapy does not appear to yield better survival benefit than standard upfront surgery, according to the results of the phase III NeoCol trial presented at ASCO 2023.

Colon cancer survival with neoadjuvant chemo vs upfront surgery a toss-up

18 Jun 2023

Low-dose atropine helps control childhood myopia progression

18 Jun 2023

The novel, preservative-free, low-dose atropine formulation NVK002 appears to be beneficial in the treatment of myopia progression in children when compared with placebo, according to the results of a phase III study.

Low-dose atropine helps control childhood myopia progression

18 Jun 2023

Is ursodeoxycholic acid beneficial in critically ill patients with sepsis?

17 Jun 2023

Critically ill patients with sepsis or septic shock who use ursodeoxycholic acid (UDCA) do not seem to experience improvement in shock severity and resolution, reveals a recent study. However, they have a higher chance of being extubated and not needing mechanical ventilation (MV) on the third day of admission to the intensive care unit (ICU).

Is ursodeoxycholic acid beneficial in critically ill patients with sepsis?

17 Jun 2023

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD

16 Jun 2023

Among women with inflammatory bowel disease (IBD), those who have long-term immunomodulator exposure are at increased risk of high-grade cervical intraepithelial neoplasia and cervical cancer (CIN2+), according to a study.

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD

16 Jun 2023

Atrial fibrillation patients use same anticoagulant after bleeding event

16 Jun 2023

A recent study has shown that the majority of patients with nonvalvular atrial fibrillation who have had a bleeding event resume anticoagulation therapy usually with the same drug class that they have been using.

Atrial fibrillation patients use same anticoagulant after bleeding event

16 Jun 2023

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

16 Jun 2023 by

Patients with Alagille syndrome (AS) may benefit from treatment with odevixibat, with the phase III ASSERT study showing that its use results in rapid, sustained, and highly significant improvements in pruritus, sleep quality, as well as decreases in bile acids (BAs). Odevixibat is also well tolerated.

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

16 Jun 2023

News & Updates

Filter by Specialty:

Specialty:

Secukinumab on par with adalimumab biosimilar in r-axSpA

Secukinumab on par with adalimumab biosimilar in r-axSpA

Cutaneous eruptions from ibrutinib overlap with EGFR-induced adverse events

Cutaneous eruptions from ibrutinib overlap with EGFR-induced adverse events

Updated CodeBreak 200 analyses boost sotorasib role in KRASG12C-mutant NSCLC

Updated CodeBreak 200 analyses boost sotorasib role in KRASG12C-mutant NSCLC

What are the barriers to communication between pharmacists during transitions of care?

What are the barriers to communication between pharmacists during transitions of care?

Colon cancer survival with neoadjuvant chemo vs upfront surgery a toss-up

Colon cancer survival with neoadjuvant chemo vs upfront surgery a toss-up

Low-dose atropine helps control childhood myopia progression

Low-dose atropine helps control childhood myopia progression

Is ursodeoxycholic acid beneficial in critically ill patients with sepsis?

Is ursodeoxycholic acid beneficial in critically ill patients with sepsis?

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD

Atrial fibrillation patients use same anticoagulant after bleeding event

Atrial fibrillation patients use same anticoagulant after bleeding event

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome